Method for producing biantennary lipid-linked oligonucleotides and intermediates

By using an amidite intermediate with protective groups and specific reagents, the synthesis of bibranched lipid-bound oligonucleotides achieves enhanced quality control, stability, and efficiency, addressing the challenges of existing methods.

JP7584410B2Active Publication Date: 2024-11-15SHIONOGI & CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2021524842
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-06-03
Filing Date
2020-06-02
Publication Date
2024-11-15
Estimated Expiration
2040-06-02

AI Technical Summary

Technical Problem

Existing methods for producing bibranched lipid-bound oligonucleotides face issues with quality control, stability, and efficiency, leading to the formation of dimers and poor condensation efficiency, as well as challenges in analyzing and managing impurities.

Method used

The introduction of an amidite intermediate with protective groups on nitrogen atoms bonded to acyl lipids, combined with specific cleavage reagents and deprotecting agents, enhances the synthesis of bibranched lipid-bound oligonucleotides by suppressing dimer formation and improving condensation efficiency, allowing for better purity control and stability.

Benefits of technology

This approach results in high-quality bibranched lipid-bound oligonucleotides with improved synthesis efficiency, stability, and effective impurity management, ensuring the desired product is obtained with minimal waste.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584410000001
    Figure 0007584410000001
  • Figure 0007584410000002
    Figure 0007584410000002
  • Figure 0007584410000003
    Figure 0007584410000003
Patent Text Reader

Abstract

Provided are: a production method in which the quality of a bifurcated lipid-linked oligonucleotide can be controlled; and an intermediate that is useful for the production method, has good stability, and is easy to manage and analyze. Specifically, this production method for a bifurcated lipid-linked oligonucleotide comprises a step for reacting an oligonucleotide with a compound represented by formula (II) (in the formula, Pro1-Pro4 each independently represent a protecting group, Pro1 and Pro2 or Pro3 and Pro4 may together form a protecting group, m, n, and p each independently represent an integer of 0-5, and Y represents a group or the like represented by formula: -P(OC2H4CN)(N(i-Pr)2)).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing a biantennary lipid-linked oligonucleotide, and further to intermediates useful in said method. [Background technology]

[0002] Patent Document 1 describes an immunostimulatory CpG oligonucleotide bound to a diacyl lipid (i.e., a biantennary lipid). Furthermore, Example 1 describes a method for synthesizing a diacyl lipid phosphoramidite and a method for synthesizing a diacyl lipid-bound oligonucleotide. Patent Documents 2 and 3 describe diacyl lipid-linked double-stranded oligonucleotides exhibiting immunostimulatory activity. Furthermore, these documents describe in Example 1 A) 1-1), 1-2) and 3) methods for synthesizing amidites having diacyl lipids, and in C) a method for synthesizing diacyl lipid-linked oligonucleotides. Patent Document 4 describes a complex in which one bibranched lipid containing two chains consisting of alkyl groups via amide at its terminal is bound to an oligonucleotide containing a nucleic acid drug such as an antisense oligonucleotide, siRNA, or microRNA (i.e., a bibranched lipid-linked oligonucleotide).Furthermore, in Example 1, A) 1) describes a method for synthesizing an amidite bound to a bibranched lipid, and C) describes a method for synthesizing a bibranched lipid-linked oligonucleotide. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] International Publication No. 2013 / 151771 [Patent Document 2] International Publication No. 2017 / 057540 [Patent Document 3] International Publication No. 2018 / 179172 [Patent Document 4] International Publication No. 2018 / 181428 Summary of the Invention [Problem to be solved by the invention]

[0004] An object of the present invention is to provide a method for producing a biantennary lipid-linked oligonucleotide that allows quality control, and to provide an intermediate useful in said method that is stable and easy to manage and analyze. [Means for solving the problem]

[0005] Patent documents 1 to 4 describe a method for obtaining a bibranched lipid-linked double-stranded oligonucleotide by introducing an intermediate (amidite) having both a diacyl lipid (bibranched lipid) and a linker unit into an oligonucleotide in a solid phase. The present inventors have found that this method produces a dimer of the oligonucleotide, and the condensation efficiency of the amidite and the oligonucleotide is poor. In order to overcome this problem, the present inventors have conducted extensive research and found that by using an amidite (the amidite of the present invention) in which two hydrogen atoms bonded to the nitrogen atom to which the acyl lipid is to be introduced are replaced with protective groups as an intermediate, and introducing the lipid after synthesizing the oligonucleotide, the production of a dimer is suppressed, the condensation efficiency of the amidite and the oligonucleotide is improved, and a bibranched lipid-linked oligonucleotide can be produced.

[0006] The present inventors further found that compounds 4-18 (compounds 5-18 in Patent Document 4, comparative compounds in the examples of the present application) described in Patent Documents 2 and 3, which are intermediates in the synthesis methods described in Patent Documents 2 to 4, have poor crystallinity and are amorphous in powder X-ray diffraction, (b) have no absorption band in a practical wavelength range when analyzed using a general UV detector, and (c) are unstable even at -20°C and decomposed over time. Furthermore, the present inventors found that (d) the efficiency of synthesizing bibranched lipid-linked oligonucleotides is relatively low when the comparative compounds are used. In contrast, as described in Example 2 below, (a') compound 5, which is an amidite (intermediate) of the present invention, had good crystallinity. Therefore, purification by crystallization was easy, and compound 5 could be obtained with a purity sufficiently better than that of the comparative compound. (b') Compound 5 has a UV absorption band generally considered to be derived from a phthaloyl group, so that analysis of purity and control and management of the amount of impurities were easy. (c') No decomposition was observed in compound 5 even at 40°C for 50 days. As a result, the quality of oligonucleotides could be guaranteed by using compound 5, whose quality was controlled by liquid chromatography equipped with a UV detector, as a raw material for oligonucleotides. Furthermore, (d') when compound 5 was used, the efficiency of bibranched lipid-linked oligonucleotide synthesis was improved compared to the conventional methods described in Patent Documents 1 to 4. The present inventors attempted to synthesize oligonucleotides bound to diacyl lipids using amidites in which only one hydrogen atom bonded to the nitrogen atom to which the acyl lipid is to be introduced is replaced by a protecting group. Using eight types of protecting groups, the synthesis of oligonucleotides from the synthesis of amidites was attempted in the same manner as in Example 1 below, but there were problems such as the synthesis of the amidites not proceeding, the amidites being unstable and gradually decomposing, and the condensation reaction of the oligonucleotides and the amidites proceeding but the protecting group applied to the amidites being unable to be deprotected. In other words, the amidites of the present invention (compounds represented by the following formula (II) or salts thereof, particularly preferably compounds represented by the following formula (I) or salts thereof) were found to be very excellent as intermediates used in an efficient synthesis method for high-quality bibranched lipid-bound oligonucleotides, compared with amidites in which only one hydrogen atom bonded to the nitrogen atom to which the acyl lipid is to be introduced is replaced by a protecting group.

[0007] Furthermore, as a result of intensive research, the present inventors have found that it is preferable to introduce compound 5 into an oligonucleotide by solid-phase synthesis to obtain compound 7, and then cleave and deprotect the compound from the solid-phase support to obtain compound 8, by protecting the amino group of cytosine in the sequence of the oligonucleotide with an acetyl group and using n-butylamine or benzylamine as a cleavage reagent and deprotection agent. That is, it has been found that both the protecting group (the protecting group of the amino group of adenine, guanine, or cytosine and the protecting group of the hydroxyl group of phosphate) and the phthaloyl group in the sequence of the oligonucleotide can be efficiently removed without causing side reactions, and the desired bibranched lipid-linked oligonucleotide can be obtained. In other words, it has been suggested that the condition of using butylamine and / or benzylamine as the cleavage reagent and deprotection agent of the present invention is particularly excellent as a method for synthesizing high-quality bibranched lipid-linked oligonucleotide compared to other conditions.

[0008] Furthermore, as a result of intensive research, the present inventors have found that amines such as alkylamines used in the steps of cleavage from the solid phase support and deprotection are inhibitors of the acylation reaction, but the amount of remaining amines can be reduced by washing compound 8 with methyl tert-butyl ether, an organic solvent. Furthermore, they have found that when benzylamine is used in the steps of cleavage from the solid phase support and deprotection, the remaining amines can be tracked and managed by UV detection, thereby improving the robustness of the acylation reaction.

[0009] That is, the present invention relates to the following. (1) Formula (I): [ka] (In the formula, A and B are each independently [ka] and X 1 , X 2 , X 3and X 4 are each independently O or S; Each q is independently an integer of 0 to 4, r and s each independently represent an integer of 0 to 3; R 1 , R 2 and R 3 each independently is halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; Here, q R 1 , r R 2 and s R 3 may be the same or different, m, n, and p each independently represent an integer of 0 to 5; Y is Formula (Y-1): -P(OR 4 )(N(R 5 )2)(wherein, R 4 is a substituted or unsubstituted alkyl; R 5 each independently represents a substituted or unsubstituted alkyl; Formula (Y-2):-P(=R 6 )(OR 7 )2(wherein, R 6 is O or S, R 7 are each independently a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkylcarbonyl, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic carbocyclic carbonyl; Formula (Y-3):-P(=R 8 )H(OR 9 )(wherein, R 8 is O or S, R 9 is a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkylcarbonyl, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic carbocyclic carbonyl. or a salt thereof. (2) A and B are each independently [ka] and X 1 and X 2 is O, The compound or salt thereof according to (1), wherein Y is a group represented by the formula (Y-1). (3) The compound according to (1) or (2) or a salt thereof, wherein the compound is represented by the following formula: [ka]

[0010] The above (1) to (3) are useful intermediates that can be used as the compound represented by formula (II) in the production method described in any one of the following (4) to (10).

[0011] (4) Formula (II): [ka] (In the formula, Pro 1 , Pro 2 , Pro 3 and Pro 4 are each independently a protecting group; Pro 1 and Pro 2 Or Pro 3 and Pro 4 may together form a protecting group, m, n, and p each independently represent an integer of 0 to 5; Y is Formula (Y-1): -P(OR 4 )(N(R 5 )2)(wherein, R 4 is a substituted or unsubstituted alkyl; R 5 each independently represents a substituted or unsubstituted alkyl; Formula (Y-2):-P(=R6 )(OR 7 )2(wherein, R 6 is O or S, R 7 are each independently a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkylcarbonyl, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic carbocyclic carbonyl; Formula (Y-3):-P(=R 8 )H(OR 9 )(wherein, R 8 is O or S, R 9 is a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkylcarbonyl, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic carbocyclic carbonyl. Formula (III): [ka] (In the formula, Support means a solid phase support, Oligonucleotide means an oligonucleotide, 3' means the 3' end of the oligonucleotide, and 5' means the 5' end of the oligonucleotide. W means a single bond or a formula: [ka] (In the formula, Z 1 is O or S, R 10 and R 11 are each independently alkyl or alkenyl; The terminal alkylene in the formula is bonded to the oxygen atom at the 3' end of the oligonucleotide, and the terminal oxygen atom in the formula is bonded to a solid support.) is a group represented by the formula (IV): [ka] (In the formula, Z 2 teeth When Y in formula (II) is a group represented by formula (Y-1), it is O or S; When Y in formula (II) is a group represented by formula (Y-2), R 6 and When Y in formula (II) is a group represented by formula (Y-3), R 8 and R 12 teeth When Y in formula (II) is a group represented by formula (Y-1), OR 4 and When Y in formula (II) is a group represented by formula (Y-2), OR 7 and When Y in formula (II) is a group represented by formula (Y-3), OR 9 and Support, Oligonucleotide, 3', 5', W, Pro 1 , Pro 2 , Pro 3 , Pro 4 wherein m, n and p are as defined above, In the presence of a cleavage reagent and a deprotection agent, the protecting group in the compound represented by formula (IV) is deprotected and cleaved from the solid support to obtain a compound represented by formula (V): [ka] (wherein each symbol is as defined above, and when W is any of the groups represented by the above formulae (a) to (d), the terminal oxygen atom in the formulae (a) to (d) is bonded to a hydrogen atom), The compound represented by formula (V), Formula (VI): R X1 -C(=O)-L 1 (In the formula, R X1 is alkyl or alkenyl, L 1 is OH or a leaving group, Formula (VII): [ka] (wherein each symbol is as defined above)

[0012] (5) Formula (II): [ka] (In the formula, Pro 1 , Pro 2 , Pro 3 and Pro 4 are each independently a protecting group; Pro 1 and Pro 2 Or Pro 3 and Pro 4 may together form a protecting group, m, n, and p each independently represent an integer of 0 to 5; Y is Formula (Y-1): -P(OR 4 )(N(R 5 )2)(wherein, R 4 is a substituted or unsubstituted alkyl; R 5 each independently represents a substituted or unsubstituted alkyl; Formula (Y-2):-P(=R 6 )(OR 7 )2(wherein, R 6 is O or S, R 7 are each independently a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkylcarbonyl, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic carbocyclic carbonyl; Formula (Y-3):-P(=R 8 )H(OR 9 )(wherein, R 8 is O or S, R 9is a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkylcarbonyl, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic carbocyclic carbonyl. Formula (III): [ka] (In the formula, Support means a solid phase support, Oligonucleotide means an oligonucleotide, 3' means the 3' end of the oligonucleotide, and 5' means the 5' end of the oligonucleotide. W means a single bond or a formula: [ka] (In the formula, Z 1 is O or S, R 10 and R 11 are each independently alkyl or alkenyl; The terminal alkylene in the formula is bonded to the oxygen atom at the 3' end of the oligonucleotide, and the terminal oxygen atom in the formula is bonded to a solid support.) is a group represented by the formula (IV): [ka] (In the formula, Z 2 teeth When Y in formula (II) is a group represented by formula (Y-1), it is O or S; When Y in formula (II) is a group represented by formula (Y-2), R 6 and When Y in formula (II) is a group represented by formula (Y-3), R 8 and R 12 teeth When Y in formula (II) is a group represented by formula (Y-1), OR 4 and When Y in formula (II) is a group represented by formula (Y-2), OR 7 and When Y in formula (II) is a group represented by formula (Y-3), OR 9 and Support, Oligonucleotide, 3', 5', W, Pro 1 , Pro 2 , Pro 3 , Pro 4 wherein m, n and p are as defined above, In the presence of a cleavage reagent and a deprotection agent, the protecting group in the compound represented by formula (IV) is deprotected and cleaved from the solid support to obtain a compound represented by formula (V): [ka] (wherein each symbol is as defined above, and when W is any of the groups represented by the above formulae (a) to (d), the terminal oxygen atom in the formulae (a) to (d) is bonded to a hydrogen atom), The compound represented by formula (V), Formula (VI): R X1 -C(=O)-L 1 (In the formula, R X1 is alkyl or alkenyl, L 1 is OH or a leaving group, to obtain a compound represented by formula (VIII): [ka] (wherein each symbol is as defined above), The compound represented by formula (VIII), Formula (IX):R X2 -C(=O)-L 2 (In the formula, R X2 is alkyl or alkenyl, L 2 is OH or a leaving group, [ka] (wherein each symbol is as defined above)

[0013] (6)R X1 is alkyl having 8 to 30 carbon atoms or alkenyl having 8 to 30 carbon atoms, R X2 is alkyl having 1 to 29 carbon atoms or alkenyl having 2 to 29 carbon atoms, The number of carbon atoms is R X1 The method according to (5), wherein the number of carbon atoms in the alkyl or alkenyl is less than or equal to 1. (7) The method according to any one of (4) to (6), wherein the cleavage reagent and the deprotection agent comprise butylamine and / or benzylamine. (8) The production method according to any one of (4) to (7), comprising a step of washing compound (V) with an organic solvent. (9) Obtaining compound (VII) or (X) by the production method according to any one of (4) to (8); The method includes a step of annealing an oligonucleotide comprising a sequence capable of hybridizing to the oligonucleotide of compound (VII) or (X) to form a double strand, A method for producing double-stranded oligonucleotides.

[0014] (10) The double-stranded oligonucleotide has the formula: [ka] (9) A method for producing a double-stranded oligonucleotide comprising a chain represented by the formula (an oligonucleotide consisting of the bases represented by SEQ ID NO: 1) and a chain represented by one of the formulae selected from the following: formula: [ka] (An oligonucleotide consisting of the bases set forth in SEQ ID NO: 2 and containing a biantennary lipid at the 5' end) ,formula: [ka] (An oligonucleotide consisting of the bases set forth in SEQ ID NO: 3 and containing a biantennary lipid at the 5' end) ,formula: [ka] (An oligonucleotide consisting of the bases set forth in SEQ ID NO: 4 and containing a biantennary lipid at the 5' end) ,formula: [ka] (An oligonucleotide consisting of the bases set forth in SEQ ID NO: 5, containing a biantennary lipid at the 5' end) ,formula: [ka] (An oligonucleotide consisting of the bases set forth in SEQ ID NO: 2 and containing a biantennary lipid at the 5' end) and the formula: [ka] (An oligonucleotide consisting of the bases set forth in SEQ ID NO: 4 and containing a biantennary lipid at the 5' end)

[0015] (11) The process according to any one of (4) to (10), wherein the compound represented by formula (II) is the compound according to (1). (12) The method according to (11), wherein the compound represented by formula (II) is the compound according to (2). (13) The method according to (11), wherein the compound represented by formula (II) is the compound according to (3).

[0016] (14) Formula (IV): [ka] (wherein each symbol is as defined above) A compound represented by the formula:

[0017] (15) Formula (XI): [ka] (wherein each symbol is as defined above) A compound represented by the formula:

[0018] (16) Formula (V): [ka] (wherein each symbol is as defined above) A compound represented by the formula:

[0019] (17) Formula (VIII): [ka] (wherein each symbol is as defined above) A compound represented by the formula: Effect of the Invention

[0020] The method and conditions for producing a biantennary lipid-linked oligonucleotide of the present invention using the amidite of the present invention in which two hydrogen atoms bonded to the nitrogen atom to which an acyl lipid is to be introduced are replaced with protecting groups are useful for suppressing the production of by-products and reliably obtaining the desired final product. In other words, the method of the present invention is very useful when synthesizing products that require high quality, such as pharmaceuticals. In particular, the intermediate compound represented by formula (I) or a salt thereof is crystalline, and quality control (purity analysis, control and management of impurity amount, etc.) is possible. Using the intermediate, biantennary lipid-linked oligonucleotides can be efficiently synthesized. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] Terms used in this specification are used in the same manner as commonly used in the art unless otherwise specified. In the present invention, any genetic manipulation method known in the art can be used, such as those described in Molecular Cloning, A Laboratory Manual, Fourth Edition, Cold Spring Harbor Laboratory Press (2012) and Current Protocols Essential Laboratory Techniques, Current Protocols (2012).

[0022] The terms used in this specification are explained below. Note that, in this specification, each term has the same meaning whether it is used alone or together with other terms.

[0023] The term "halogen" includes fluorine, chlorine, bromine and iodine atoms. In particular, fluorine and chlorine atoms are preferred.

[0024] The term "alkyl" includes straight-chain or branched hydrocarbon groups having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, and even more preferably 1 to 4 carbon atoms. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, and n-decyl. Preferred embodiments of "alkyl" include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl. In addition, R in formula (VI) X1 and R in formula (IX) X2 The "alkyl" in the above formula includes straight-chain or branched hydrocarbon groups having 1 to 50, 1 to 40, or 1 to 30 carbon atoms, more preferably 8 to 30 carbon atoms, and even more preferably 12 to 30 carbon atoms.

[0025] The term "alkenyl" includes linear or branched hydrocarbon groups having one or more double bonds at any position and having 2 to 15 carbon atoms, preferably 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, and even more preferably 2 to 4 carbon atoms. Examples include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, and pentadecenyl. Preferred embodiments of "alkenyl" include vinyl, allyl, propenyl, isopropenyl and butenyl. In addition, R in formula (VI) X1 and R in formula (IX) X2 The "alkenyl" in the above formula includes a straight-chain or branched hydrocarbon group having one or more double bonds at any position and having 2 to 50, 2 to 40, or 2 to 30 carbon atoms, more preferably 8 to 30 carbon atoms, and even more preferably 12 to 30 carbon atoms.

[0026] The term "alkynyl" refers to a linear or branched hydrocarbon group having 2 to 10 carbon atoms, preferably 2 to 8 carbon atoms, more preferably 2 to 6 carbon atoms, and even more preferably 2 to 4 carbon atoms, which has one or more triple bonds at any position. It may further have a double bond at any position. Examples of the group include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, and decynyl. A preferred embodiment of "alkynyl" is ethynyl, propynyl, butynyl or pentynyl.

[0027] The term "aromatic carbocyclic group" refers to a monocyclic or bicyclic or more aromatic hydrocarbon group, such as phenyl, naphthyl, anthryl, and phenanthryl. A preferred embodiment of the "aromatic carbocyclic group" is phenyl.

[0028] Substituents for the "substituted alkyl", "substituted alkenyl" and "substituted alkynyl" include the following substituents. Any carbon atom may be bonded to one or more groups selected from the following substituents. Substituents: halogen, hydroxy, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfo, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azido, hydrazino, ureido, amidino, guanidino, trialkylsilyl, alkyloxy, alkenyloxy, alkynyloxy, haloalkyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, monoalkyla amine, dialkylamino, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, monoalkylcarbonylamino, dialkylcarbonylamino, monoalkylsulfonylamino, dialkylsulfonylamino, alkylimino, alkenylimino, alkynylimino, alkylcarbonylimino, alkenylcarbonylimino, alkynylcarbonylimino, alkyloxyimino, alkenyloxyimino, alkynyloxyimino, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy oxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylsulfanyl, alkenylsulfanyl, alkynylsulfanyl, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, monoalkylcarbamoyl, dialkylcarbamoyl, monoalkylsulfamoyl, dialkylsulfamoyl, aromatic carbocyclic group, non-aromatic carbocyclic group, aromatic heterocyclic group, non-aromatic heterocyclic group, aromatic carbocyclic oxy, non-aromatic carbocyclic oxy, aromatic heterocyclic oxy, non-aromatic heterocyclic oxy, aromatic carbocyclic carbonyl, non-aromatic carbocyclic carbonyl, aromatic heterocyclic carbonyl, non-aromatic heterocyclic carbonyl, aromatic carbocyclic oxycarbonyl, non-aromatic carbocyclic oxycarbonyl, aromatic heterocyclic oxycarbonyl, non-aromatic heterocyclic oxycarbonyl, aromatic carbocyclic alkyloxy, non-aromatic carbocyclic alkyloxy, aromatic heterocyclic alkyloxy, non-aromatic heterocyclic alkyloxy, aromatic carbocyclic alkyloxycarbonyl, non-aromatic carbocyclic alkyloxycarbonyl, aromatic heterocyclic alkyloxycarbonyl, non-aromatic heterocyclic alkyloxycarbonyl, aromatic carbocyclic alkylamino,Non-aromatic carbocyclic alkylamino, aromatic heterocyclic alkylamino, non-aromatic heterocyclic alkylamino, aromatic carbocyclic sulfanyl, non-aromatic carbocyclic sulfanyl, aromatic heterocyclic sulfanyl, non-aromatic heterocyclic sulfanyl, non-aromatic carbocyclic sulfonyl, aromatic carbocyclic sulfonyl, aromatic heterocyclic sulfonyl and non-aromatic heterocyclic sulfonyl.

[0029] Substituents on the ring of the "substituted aromatic carbocycle", "substituted non-aromatic carbocycle", "substituted aromatic heterocycle" and "substituted non-aromatic heterocycle" include the following substituents. An atom at any position on the ring may be bonded to one or more groups selected from the following substituents. Substituents: halogen, hydroxy, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfo, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azido, hydrazino, ureido, amidino, guanidino, trialkylsilyl, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxy, alkenyloxy, alkynyloxy, haloalkyloxy, alkyloxyalkyl, a alkyloxyalkyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, monoalkylamino, dialkylamino, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, monoalkylcarbonylamino, dialkylcarbonylamino, monoalkylsulfonylamino, dialkylsulfonylamino, alkylimino, alkenylimino, alkynylimino, alkylcarbonylimino, alkenylcarbonylimino, alkynylcarbonylimino, alkyloxyimino, alkenyl ... Quinyloxyimino, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylsulfanyl, alkenylsulfanyl, alkynylsulfanyl, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, monoalkylcarbamoyl, dialkylcarbamoyl, monoalkylsulfamoyl, dialkylsulfamoyl, aromatic carbocyclic group, non-aromatic carbocyclic group, aromatic heterocyclic group, non-aromatic heterocyclic group aromatic cyclic group, aromatic carbocyclic oxy, non-aromatic carbocyclic oxy, aromatic heterocyclic oxy, non-aromatic heterocyclic oxy, aromatic carbocyclic carbonyl, non-aromatic carbocyclic carbonyl, aromatic heterocyclic carbonyl, non-aromatic heterocyclic carbonyl, aromatic carbocyclic oxycarbonyl, non-aromatic carbocyclic oxycarbonyl, aromatic heterocyclic oxycarbonyl, non-aromatic heterocyclic oxycarbonyl, aromatic carbocyclic alkyl, non-aromatic carbocyclic alkyl, aromatic heterocyclic alkyl, non-aromatic heterocyclic alkyl, aromatic carbocyclic alkyloxy, non-aromatic carbocyclic alkyloxy, aromatic heterocyclic alkyloxy,Non-aromatic heterocyclic alkyloxy, aromatic carbocyclic alkyloxycarbonyl, non-aromatic carbocyclic alkyloxycarbonyl, aromatic heterocyclic alkyloxycarbonyl, non-aromatic heterocyclic alkyloxycarbonyl, aromatic carbocyclic alkyloxyalkyl, non-aromatic carbocyclic alkyloxyalkyl, aromatic heterocyclic alkyloxyalkyl, non-aromatic heterocyclic alkyloxyalkyl, aromatic carbocyclic alkylamino, non-aromatic carbocyclic alkylamino, aromatic heterocyclic alkylamino, non-aromatic heterocyclic alkylamino, aromatic carbocyclic sulfanyl, non-aromatic carbocyclic sulfanyl, aromatic heterocyclic sulfanyl, non-aromatic heterocyclic sulfanyl, non-aromatic carbocyclic sulfonyl, aromatic carbocyclic sulfonyl, aromatic heterocyclic sulfonyl and non-aromatic heterocyclic sulfonyl.

[0030] The method for producing the biantennary lipid-linked oligonucleotide of the present invention includes the methods described in (4) to (13) above.

[0031] The production method of the present invention described in (4) above will be described below. [ka] (In the formula, each symbol has the same meaning as defined above.)

[0032] Regarding the production method of the present invention described in the above (5), the steps after obtaining the compound represented by formula (V) are shown below. The steps up to obtaining the compound represented by formula (V) are the same as those in the above (4). [ka] (wherein each symbol has the same meaning as defined above)

[0033] 1. Synthesis of Oligonucleotides The compound represented by formula (II) or a salt thereof is reacted with the oligonucleotide represented by formula (III) to obtain the compound represented by formula (IV). As a synthesis method, a solid-phase synthesis method using phosphoramidite can be used. For example, it is disclosed in the following examples, Tetrahedron Letters 22, 1859-1862 (1981), etc. Specifically, the compound represented by formula (III) is first synthesized using a commercially available automatic nucleic acid synthesizer (for example, GE Healthcare (Cytiva), AppliedBiosystems, Dai Nippon Seiki Co., Ltd., etc.), and in the final cycle, the compound represented by formula (II) or a salt thereof is introduced, whereby the compound represented by formula (IV) can be easily synthesized.

[0034] The term "solid phase carrier" refers to a solid support that can support oligonucleotides and is insoluble in a reaction solvent, and is used in solid-phase synthesis of oligonucleotides. Commercially available products that are commonly used in the art can be used as solid phase carriers in the production method of the present invention, and the functional groups present on the surface of the carriers of these commercially available products can be appropriately modified as necessary. The compound represented by formula (II) or a salt thereof can be prepared by adding each protecting group (Pro 1 , Pro 2 , Pro 3 and Pro 4 ) can be introduced to produce the compound.

[0035] The term "oligonucleotide" refers to a nucleotide consisting of multiple identical or different nucleosides linked together. The sequence or modification of the "oligonucleotide" in the present invention is not particularly limited. DNA, RNA, or nucleic acids containing nucleotides having modifications known in the art in the nucleic acid base, sugar, or internucleoside bond can be used. The chain length of the oligonucleotide is not particularly limited, and is, for example, 8 to 50 bases, 8 to 40 bases, 8 to 30 bases, 10 to 25 bases, or 15 to 25 bases.

[0036] In the present specification, the term "Oligonuclide" in formulas (III) to (V), (VII), (VIII), (X) and (XI) is used. l The O bonded to the left of "eotide" represents the oxygen atom at the 3' end of the oligonucleotide sequence, and the O bonded to the right represents the oxygen atom at the 5' end of the oligonucleotide sequence. "Oligonuc" l The "eotide" is not particularly limited as long as it is an oligonucleotide that requires the binding of a bibranched lipid. Examples include the CpG oligonucleotide described in Patent Document 1, the "oligonucleotide containing a sequence capable of hybridizing to a CpG oligonucleotide" described in Patent Documents 2 and 3, and the "oligonucleotide having activity of suppressing expression of a target gene (single strand of a double stranded oligonucleotide such as siRNA or miRNA, antisense oligonucleotide, etc.)" described in Patent Document 4. By binding a bibranched lipid, the pharmaceutical activity (immunostimulatory activity in the case of an adjuvant, target gene expression suppression activity in the case of a nucleic acid drug, etc.) of the oligonucleotide to which the lipid is bound or the oligonucleotide containing a sequence capable of hybridizing to the oligonucleotide can be improved.

[0037] In this specification, the term "Oligonuclide" in formulas (III), (IV) and (XI) is used. lThe amino moieties in adenine, guanine or cytosine in "eotide" and the hydroxy moieties in phosphoric acid are protected with a protecting group to prevent side reactions. Protective groups commonly used in the art can be used as the protecting group. For example, the protecting group for amino includes pivaloyl, pivaloyloxymethyl, trifluoroacetyl, phenoxyacetyl, 4-isopropylphenoxyacetyl, 4-tert-butylphenoxyacetyl, acetyl, benzoyl, isobutyryl, dimethylaminomethylene 9-fluorenylmethyloxycarbonyl, and the like. Phenoxyacetyl, 4-isopropylphenoxyacetyl, acetyl, benzoyl, isobutyryl, or dimethylformamidinyl groups are preferred. The protecting group for the amino moiety of adenine is particularly preferably a benzoyl group. The protecting group for the amino moiety of guanine is particularly preferably a dimethylaminomethylene group or an isobutyryl group. The protecting group for the amino moiety of cytosine is particularly preferably a benzoyl group or an acetyl group, and more preferably an acetyl group. The protecting group for the hydroxy group of phosphoric acid may be 2-cyanoethyl or the like.

[0038] Pro 1 , Pro 2 , Pro 3 and Pro 4 The "protecting group" in is not particularly limited as long as it can stably protect amino during nucleic acid synthesis. Specifically, it refers to a protecting group that is stable under acidic or neutral conditions and can be cleaved by a chemical method such as hydrogenolysis, hydrolysis, electrolysis, and photolysis, and examples thereof include formyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, and the like.

[0039] "Pro 1 and Pro 2 Or Pro 3 and Pro 4 "together form a protecting group" means that Pro 1 and Pro 2 Or Pro 3 and Pro4 are taken together to form a protecting group containing a nitrogen-containing ring. The protecting group is not particularly limited, but examples thereof include [ka] (wherein each symbol has the same meaning as defined above) is exemplified.

[0040] The compound represented by formula (II) is preferably in the following form. As m, among integers of 0 to 5, 0 to 2 is preferable, and 1 is particularly preferable. As n, among integers of 0 to 5, 1 or 2 is preferable, and 1 is particularly preferable. As p, among integers of 0 to 5, 0 or 1 is preferable, and 0 is particularly preferable. Examples of Y include a group represented by formula (Y-1), a group represented by formula (Y-2), or a group represented by formula (Y-3). R 4 is preferably alkyl or cyanoalkyl. 5 is preferably alkyl. Examples of the formula (Y-1) include a group represented by the formula: -P(OC2H4CN)(N(i-Pr)2) (wherein i-Pr is isopropyl). R 6 is preferably O, R 7 is preferably a hydrogen atom. An example of the formula (Y-2) is a group represented by the formula: -P(=O)(OH)2. R 8 is preferably O, R 9 is preferably a hydrogen atom. Examples of the formula (Y-3) include a group represented by the formula: -P(=O)H(OH).

[0041] Particularly preferred examples of the compound represented by formula (II) include the compound represented by formula (I) and salts thereof. More preferred examples include the compounds described in (2) or (3) above and salts thereof.

[0042] The compound represented by formula (I) is preferably in the following form. A and B are each independently [ka] It is preferred that: X 1 , X 2 , X 3 and X 4 is preferably O. Y is preferably a group represented by the formula (Y-1). Particularly preferred compounds represented by formula (I) are compounds represented by the following formulas or salts thereof. [ka]

[0043] One or more hydrogen, carbon or other atoms of the compounds of formula (I) or (II) of the present invention may be replaced with an isotope of the hydrogen, carbon or other atom. For example, compounds of formula (I) or (II) include all radiolabeled forms of compounds of formula (I) or (II). Each of such "radiolabeled", "radiolabeled forms" of compounds of formula (I) or (II) is included in the present invention and is useful as a research and / or diagnostic tool in metabolism pharmacokinetic studies and binding assays. Examples of isotopes that can be incorporated into compounds of formula (I) or (II) of the present invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively. Radiolabeled compounds of the present invention can be prepared by methods well known in the art. For example, tritium-labeled compounds of formula (I) or (II) can be prepared by introducing tritium into a particular compound of formula (I) or (II), for example, by catalytic dehalogenation reaction with tritium. The method may include reacting a suitable halogen-substituted precursor of the compound of formula (I) or (II) with tritium gas in the presence of a suitable catalyst, such as Pd / C, with or without a base. For suitable methods for preparing other tritium-labeled compounds, see the document Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987). 14C-labeled compounds can be prepared by using a raw material having 14C carbon.

[0044] Salts of the compounds of formula (I) or (II) include the following salts. Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts; aliphatic amine salts such as trimethylamine salts, triethylamine salts, dicyclohexylamine salts, ethanolamine salts, diethanolamine salts, triethanolamine salts, brocaine salts, meglumine salts, diethanolamine salts, and ethylenediamine salts; aralkylamine salts such as N,N-dibenzylethylenediamine and benethamine salts; heterocyclic aromatic amine salts such as pyridine salts, picoline salts, quinoline salts, and isoquinoline salts; quaternary ammonium salts such as tetramethylammonium salts, tetraethylammonium salts, benzyltrimethylammonium salts, benzyltriethylammonium salts, benzyltributylammonium salts, methyltrioctylammonium salts, and tetrabutylammonium salts; and basic amino acid salts such as arginine salts and lysine salts. Examples of acid salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, hydrogencarbonate, perchlorate, etc.; organic acid salts such as benzoate, acetate, propionate, lactate, maleate, fumarate, tartrate, malate, citrate, ascorbate, etc.; sulfonate salts such as methanesulfonate, isethionate, benzenesulfonate, p-toluenesulfonate, etc.; acidic amino acids such as aspartate, glutamate, etc. In the present specification, the acid addition salts include the above-mentioned acid salts.

[0045] The compound of formula (I) or (II) or its salt may form a solvate and / or a crystal polymorph, and the compound of formula (I) or (II) includes such various solvates and crystal polymorphs. The solvate means a solvate of the compound of formula (I) or (II) or its salt, and examples thereof include an alcohol (e.g., ethanol) solvate, a hydrate, a toluene solvate, etc. Examples of the hydrate include a monohydrate and a dihydrate. The "solvate" may be coordinated with any number of solvent molecules (e.g., water molecules, etc.) to the compound of formula (I) or (II). When the compound of formula (I) or (II) or its salt is left in the air, it may absorb moisture, and adsorbed water may adhere to it, or a hydrate may be formed. In addition, the compound of formula (I) or (II) or its salt may be recrystallized to form a crystal polymorph.

[0046] A general method for producing the compound of the present invention represented by formula (I) is exemplified below. Extraction, purification, etc. may be carried out by treatments generally used in organic chemistry experiments. An example of the production method when A and B in the compound represented by formula (I) are the same is shown below. [ka] (In the formula, each symbol has the same meaning as in formula (I).)

[0047] Process 1-1 Add acetonitrile to compound (b) and stir. Add triethylamine, then add a solution of compound (a) dissolved in acetonitrile and acetonitrile. Stir vigorously and filter the solid. Wash the resulting solid with acetonitrile and dry it to obtain compound (c).

[0048] Process 2-1 Compound (c) obtained in step 1-1 and N-methylpyrrolidone are added to N-methylpyrrolidone and stirred. N,N-diisopropylethylamine is added, and then compound (d) and N-methylpyrrolidone are added. Stir at room temperature, add tap water, and further stir. Add tap water and stir. Then, add tap water again, stir, and filter the solid. Wash the obtained solid with 2-propanol and dry to obtain compound (I-1).

[0049] In the compound of formula (I), an example of the production method when A and B are different is shown below. [ka] (In the formula, R 1-1 and R 1-2 is R in formula (I) 1 Equivalent to X 1-1 and X 1-2 is X in formula (I) 1 Equivalent to X 2-1 and X 2-2 is X in formula (I) 2 q-1 and q-2 are the same as q in formula (I), and the other symbols are the same as in formula (I).

[0050] Process 1-2 In the above step 1-1, the amount of compound (b) added is reduced to obtain compound (e). Next, compound (f) is added to compound (e) to obtain compound (g). Process 2-2 The obtained compound (g) is used to obtain compound (I-2) in the same manner as in step 2-1 above. Instead of compounds (b) and (f), a compound of the formula: [ka] A compound represented by the following formula can be used.

[0051] 2. Cleavage from resin and deprotection of base and phosphate In the presence of a cleavage reagent and a deprotection agent, the protecting groups in the compound represented by formula (IV) (including the protecting groups of the base and phosphate in the oligonucleotide) are deprotected and the compound is cleaved from the solid support to obtain the compound represented by formula (V).

[0052] The steps of deprotection and cleavage from the solid support can be performed simultaneously, can be performed with the same reagent or with two or more reagents, can be performed at different temperatures and with different reagents. The "cleavage reagent and deprotection agent" may be any reagent commonly used in the field, so long as it has the effect of cleaving an oligonucleotide from a solid support and / or deprotecting a protecting group. Examples include ammonia, amines, etc. Preferably, it contains butylamine and / or benzylamine. Particularly preferably, it contains n-butylamine or benzylamine. Furthermore, when the oligonucleotide sequence contains cytosine, it is preferable to synthesize the oligonucleotide using an amidite in which the amino group of cytosine is protected with an acetyl group, and then use a cleavage reagent and deprotection agent containing n-butylamine or benzylamine. First, diethylamine was used to remove R 12 The protecting group contained in the compound represented by formula (IV) can then be removed, followed by deprotection of other protecting groups in the compound represented by formula (IV) and cleavage from the solid support.

[0053] 3. Introduction of lipids (acylation reaction) The compound represented by formula (VII) is obtained by reacting the compound represented by formula (V) with the compound represented by formula (VI). Furthermore, a compound represented by formula (V) is reacted with a compound represented by formula (VI) to obtain a compound represented by formula (VIII), and a compound represented by formula (IX) is reacted with a compound represented by formula (X).

[0054] In the above-mentioned step of introducing the lipid, it is preferable to wash the compound represented by formula (V) with an organic solvent before reacting the compound represented by formula (VI) with the compound represented by formula (V). Examples of the "organic solvent" include hexane, heptane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, cyclopropyl methyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, anisole, toluene, methyl isobutyl ketone, methyl ethyl ketone, ethyl acetate, isopropyl acetate, n-butyl acetate, n-butanol, dichloromethane, chloroform, etc. Particularly preferred is methyl tert-butyl ether.

[0055] R X1 is alkyl or alkenyl, and preferably alkyl having 8 to 30 carbon atoms or alkenyl having 8 to 30 carbon atoms. R X2 is alkyl or alkenyl, preferably alkyl having 1 to 29 carbon atoms or alkenyl having 2 to 29 carbon atoms. X2 The number of carbon atoms in the alkyl or alkenyl in R X1 It is preferable that the number of carbon atoms in the alkyl or alkenyl is less than or equal to 1.

[0056] L 1 and L 2The "leaving group" in is not particularly limited as long as it is a substituent that is eliminated during condensation of a carboxylic acid with an amine. Examples thereof include halogen, substituted or unsubstituted alkylimino, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkylsulfonyloxy, substituted or unsubstituted aromatic carbocyclic oxy, substituted or unsubstituted non-aromatic carbocyclic oxy, substituted or unsubstituted aromatic heterocyclic oxy, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic sulfonyloxy, substituted or unsubstituted aromatic carbocyclic alkylsulfonyloxy, and the like. Preferred are halogen, acetyloxy, benzoyloxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, paratoluenesulfonyloxy, orthonitrobenzenesulfonyloxy, N,N'-dicyclohexylcarbamimidoyloxy, N,N'-diisopropylcarbamimidoyloxy, (N-(3-(dimethylamino)propyl)-N'-ethylcarbamimidoyloxy, N-succinimidyloxy and the like. Particularly preferred is N-succinimidyloxy. In this step, a condensation agent can be used. As the condensation agent, an amide condensation agent used for condensation of a carboxyl group and an amino group can be used. For example, carbodiimides (e.g., N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, diphenylphosphoryl azide, BOP reagents (e.g., BOP, PyBop, TBTU, etc.), HBTU, DMT-MM, 1,1'-carbonylbis-1H-imidazole, 2-chloro-1,3-dimethylimidazolium chloride, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, N-hydroxysuccinimide, sodium N-hydroxysuccinimide, etc. are preferred. N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N-hydroxysuccinimide, sodium N-hydroxysuccinimide, etc. )Particularly preferred is N-hydroxysuccinimide or N,N'-dicyclohexylcarbodiimide. L 1 Or L 2 When is OH, it is preferable to use a condensing agent.

[0057] The biantennary lipid-linked oligonucleotide (single-stranded) obtained by the production method of the present invention can be used, for example, as a nucleic acid drug such as an antisense drug.

[0058] 4. Preparation of Double-stranded Oligonucleotides A double-stranded oligonucleotide is obtained by annealing an oligonucleotide containing a sequence capable of hybridizing to the oligonucleotide of compound (VII) or (X) obtained by the above-mentioned production methods A to C. The annealing oligonucleotide may be one or several bases shorter than the oligonucleotide in compound (VII) or (X) so long as it hybridizes with the oligonucleotide in compound (VII) or (X), or may be longer than the oligonucleotide in compound (VII) or (X) by adding one or several bases to one or both sides of the hybridizing site. "One or several bases" means 1 to 10, 1 to 5, 1 to 3, or 1 or 2 bases. The preferred length of the annealing oligonucleotide depends on the length of the oligonucleotide in compound (VII) or (X). For example, it is 50% or more, 60% or more, 70% or more, 50 to 100%, 60 to 100%, or 70 to 100% of the length of the oligonucleotide chain in compound (VII) or (X). Particularly preferred is 50 to 100% of the length of the oligonucleotide chain in compound (VII) or (X).

[0059] The annealing oligonucleotide may have one or several mismatches at the hybridization site, as long as it can hybridize with the oligonucleotide in compound (VII) or (X) under stringent conditions. For example, the hybridization site may have at least 70% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more homology with the target sequence. Here, the homology is expressed as a score obtained by using the search program BLAST, which uses the algorithm developed by Altschul et al. (The Journal of Molecular Biology, 215, 403-410 (1990)).

[0060] "Stringent conditions" refers to conditions under which a certain base sequence forms a hybrid (so-called specific hybrid) with a specific sequence, and a base sequence that does not have an equivalent function does not form a hybrid (so-called non-specific hybrid) with the specific sequence. Those skilled in the art can easily select such conditions by changing the temperature during hybridization reaction and washing, the salt concentration of the hybridization reaction solution and washing solution, etc. Specifically, the conditions of hybridization in 6xSSC (0.9M NaCl, 0.09M trisodium citrate) or 6xSSPE (3M NaCl, 0.2M NaH2PO4, 20mM EDTA·2Na, pH 7.4) at 42°C, and further washing with 0.5xSSC at 42°C are given as examples of stringent conditions of the present invention, but are not limited thereto. As a hybridization method, a method well known and commonly used in the art, such as Southern blot hybridization, can be used. Specifically, this can be carried out in accordance with the methods described in Molecular Cloning: A Laboratory Manual, Second Edition (1989) (Cold Spring Harbor Laboratory Press), Current Protocols in Molecular Biology (1994) (Wiley-Interscience), DNA Cloning 1: Core Techniques, A Practical Approach, Second Edition (1995) (Oxford University Press), etc.

[0061] "One or several mismatches" means 1 to 5, preferably 1 to 3, and more preferably 1 or 2 mismatches.

[0062] The biantennary lipid-linked oligonucleotide (double strand) obtained by the method of the present invention can be used as the method of producing a biantennary lipid-linked oligonucleotide described in Patent Documents 2 to 4, for example, as described in (10) above.

[0063] Unless otherwise noted, numerical values ​​given in the specification and claims are approximate and variations in numerical values ​​are due to instrument calibration, instrument error, purity of materials, crystal size, sample size, and other factors.

[0064] Various substituents of the compound of the present invention can be introduced with reference to (1) Alan R. Katriszly et al., Comprehensive Heterocyclic Chemistry, (2) Alan R. Katriszly et al., Comprehensive Heterocyclic Chemistry II, (3) RODD'S CHEMISTRY OF CARBON COMPOUNDS VOLUME IV HETEROCYCLIC COMPOUNDS, etc. EXAMPLES

[0065] The present invention will be described in more detail below by way of examples of the present invention, but the present invention is not limited to these examples. NMR analysis of the compounds obtained in the examples was carried out using a 400 MHz superconducting nuclear magnetic resonance apparatus, and measurements were performed using CDCl3.

[0066] Example 1 Synthesis of biantennary lipid-linked oligonucleotide using the intermediate (amidite) of the present invention 1) Synthesis of amidites [ka]

[0067] Process 1 Acetonitrile (600 mL) was added to compound 2 (133.76 g, 610.22 mmol) and stirred. Triethylamine (30.87 g, 305.07 mmol) was added, and then a solution of compound 1 (25.00 g, 277.38 mmol) dissolved in acetonitrile (125 mL) and acetonitrile (25 mL) were added. The mixture was stirred vigorously at room temperature for 2.5 hours, and the solid was filtered off. The obtained solid was washed with acetonitrile (300 mL) and then dried to obtain compound 3 (72.73 g, 207.6 mmol) as a white solid.

[0068] The UPLC analysis was carried out under the following conditions. Mobile phase: [A] is 60 mM ammonia-ammonium acetate buffer solution (pH 8.0), [B] is acetonitrile Gradient: A linear gradient of 15%-50% solvent [B] in 12 min, followed by a linear gradient of 50%-95% solvent [B] in 3 min, maintained at 95% solvent [B] for 1 min. Column: ACQUITY UPLC® BEH Phenyl (1.7 μm, id 2.1 x 100 mm) (Waters) Flow rate: 0.3 mL / min UV detection wavelength: 295 nm

[0069] 1 H-NMR(CDCl3)δ:7.85-7.90 (m, 4H), 7.72-7.76 (m, 4H), 4.28-4.34 (m, 1H), 3.83-3.93 (m, 4H), 3.12 (d, 1H, J = 6.3 Hz). 13 C-NMR(CDCl3)δ:42.21, 68.75, 123.53, 131.94, 134.19, 168.68. ESI-MS(m / z): 351 (M+1), 373 (M+23).

[0070] Process 2 Compound 3 (20.00 g, 57.09 mmol) and N-methylpyrrolidone (10 mL) were added to N-methylpyrrolidone (220 mL) and stirred. N,N-diisopropylethylamine (20.68 g, 160.01 mmol) was added, and then compound 4 (21.62 g, 91.35 mmol) and N-methylpyrrolidone (10 mL) were added. The mixture was stirred at 23°C for 1.5 hours, tap water (20.00 g) was added, and the mixture was stirred for another 0.5 hours. Tap water (50.00 g) was added over 15 minutes, and the mixture was stirred for 2 hours. Then, tap water (70.02 g) was added over 22 minutes, and the mixture was stirred for 1.5 hours, and the solid was filtered. The obtained solid was washed with 2-propanol (80 mL), dried, and compound 5 (27.83 g, 50.55 mmol) was obtained as a white solid.

[0071] 1 H-NMR(CDCl3)δ:7.82-7.88 (m, 4H), 7.70-7.7.76 (m, 4H), 4.40-4.49 (m, 1H), 3.94-4.07 (m, 2H), 3.66-3.80 (m, 3H), 3.38-3.56 (m, 3H), 2.38-2.52 (m, 2H), 0.97-1.01 (m, 12H). 13 C-NMR(CDCl3)δ:19.8 (d, J = 6.6 Hz), 24.19, 24.24, 24.47, 24.53, 41.2, 41.3, 41.4, 43.0, 43.1, 58.2 (d, J = 21.1 Hz), 68.3 (d, J = 10.9 Hz), 117.4, 123.2, 123.3, 132.1, 132.2, 133.97, 134.02, 168.0, 168.1. 31 P-NMR(CDCl3) δ: 149.3 ESI-MS(m / z): 551 (M+1), 573 (M+23).

[0072] 2) Synthesis of lipid-linked oligonucleotides The UPLC analysis was carried out under the following conditions. Mobile phase: [A] is 200 mM 1,1,1,3,3,3-hexafluoro-2-propanol, 8 mM triethylamine in aqueous solution [B] is 200 mM 1,1,1,3,3,3-hexafluoro-2-propanol, 8 mM triethylamine in methanol solution Gradient: A linear gradient from 5% to 26% solvent [B] in 7.29 minutes, followed by a linear gradient from 26% to 55% solvent [B] in 1.21 minutes, a linear gradient from 55% to 95% solvent [B] in 3.64 minutes, and maintained at 95% solvent [B] for 2.86 minutes. Column: ACQUITY UPLC® Protein BEH C4, 300 Å (1.7 μm, id 2.1x50 mm) (Waters) Flow rate: 0.51 mL / min UV detection wavelength: 254 nm Column temperature: 45℃

[0073] [ka] (In the formula, each symbol is as defined above, and n' is an integer of 6 to 28.)

[0074] 2-1) Synthesis of oligonucleotides The oligonucleotides were synthesized by the phosphoramidite method using an automatic nucleic acid synthesizer, AKTA Oligopilot100 (GE Healthcare (Cytiva)), NS-8-I (Dainippon Seiki), and NS-8-II (Dainippon Seiki). The coupling time was 3 minutes, and 2 to 10 equivalents of amidite were used for condensation of one monomer. In the final cycle, 5 equivalents of compound 5 was prepared in 0.2 M acetonitrile solution and added as the monomer to be introduced to the obtained compound 6, and the coupling time was 60 minutes to obtain compound 7. For PO oxidation, 0.02M Oxidizer (Sigma-Aldrich) and iodine / pyridine / water = 12.7 / 9 / 1 (w / v / v) were used. For PS oxidation, 0.2M xanthan hydride in pyridine solution and 50mM DDTT ((dimethylamino-methylidene)amino-3H-1,2,4-dithiazoline-3-thione) in acetonitrile / 3-picoline 1 / 1 (v / v), 1 / 4 (v / v), and acetonitrile / pyridine 1 / 4 (v / v) solutions were used. Activators used were BTT activator (5-benzylthio)-1H-tetrazole) (Sigma-Aldrich), ETT activator (5-ethylthio)-1H-tetrazole) (Sigma-Aldrich), and capping reagents were CapA and CapB (Sigma-Aldrich). . Escape The tritylating reagents were Deb (3w / v% TCA CH2Cl2 solution) (Wako Pure Chemical Industries, Ltd.), Deb (3w / v% Dichloroaceti c Acid, Toluene Solution) were used.

[0075] 2-2) Cleavage from resin, deprotection of base and phosphate Cleavage of compound 8 from the solid support, deprotection of the benzoyl group protecting the amino group of adenine in the oligonucleotide, the isobutyryl group protecting the amino group of guanine, the acetyl group protecting the amino group of cytosine, and the 2-cyanoethyl group protecting the hydroxyl group of phosphate, and deprotection of the phthaloyl group were carried out using aqueous ammonia and n-butylamine by vigorously stirring at room temperature for 4 hours and at 55°C for 2 hours. Alternatively, aqueous ammonia and benzylamine were used and the mixture was stirred vigorously at room temperature for 4 hours and at 55° C. for 4 hours. In addition, it was revealed that the target lipid introduction reaction stops if amines remain in "2-4) Lipid introduction". However, when benzylamine was used, it was possible to track and manage the remaining benzylamine by a UV detector (254 nm) in the washing by liquid separation operation described in this section and in "2-3) Purification of compound 8". In addition, in the separation operation described in this section, it was effective to remove amines by washing with methyl tert-butyl ether. Specifically, the resin after cleavage from the reaction mixture was filtered, and the obtained resin was washed with water and methyl tert-butyl ether. The combined solution of the filtrate and the washings was washed with methyl tert-butyl ether by separation operation, and then concentrated under reduced pressure to about 75% of the weight to obtain a crude solution of compound 8.

[0076] 2-3) Purification of compound 8 The crude solution of compound 8 was purified by reverse phase liquid chromatography under the following conditions: The obtained fractions were collected and concentrated under reduced pressure to about 80% of the weight to obtain a solution of compound 8. (Purification conditions) Mobile phase: [A] is an aqueous solution containing 100 mM sodium acetate, [B] is acetonitrile Gradient: 0% solvent [B] for 59 min, followed by a linear gradient of 0%-5% solvent [B] in 1 min, a linear gradient of 5%-90% solvent [B] in 30 min, followed by a 95% solvent [B] hold for 10 min. Column: Triart Prep® C18-S (12 nm, id 10x250 mm) (YMC) Flow rate: 5mL / min UV detection wavelength: 254 nm Column temperature: 25℃

[0077] 2-4) Introduction of lipids Compound 9-n' (e.g., n'=18, arachidic acid), N-hydroxysuccinimide and N,N'-dicyclohexylcarbodiimide were dissolved in N-methylopyrrolidone, stirred at 50°C for 2 hours, diluted with N-methylopyrrolidone, and the solution of compound 8 was added. After stirring at room temperature for 2 hours, ethanol and an aqueous solution containing 1M sodium acetate were added, and the solid was filtered off. The obtained solid was washed with ethanol and methyl tert-butyl ether, and the washings were combined with the filtrate.

[0078] 3) Purification, desalting, and lyophilization of compound 10-n' The obtained solid is subjected to a method similar to that described in E) purification and F) desalting and lyophilization of purified oligonucleotide in Example 1 of Patent Document 2 to synthesize compound 10-n'.

[0079] 4) Preparation of double-stranded oligonucleotides According to the method described in I) Preparation of double-stranded oligonucleotide in Example 1 of Patent Document 2, an oligonucleotide containing a sequence capable of hybridizing with compound 10-n' is synthesized, and then annealed with compound 10-n' to prepare a double-stranded nucleic acid, thereby obtaining compounds XI-1 to XI-6.

[0080] [Table 1]

[0081] Moreover, siRNA-4 and siRNA-5 described in Table 14 of Patent Document 4 are obtained by a similar method.

[0082] Example 2 Physical properties of the intermediate (amidite) of the present invention The physical properties of compound 5 were compared with those of the following comparative compounds (compounds 4-18 described in Patent Documents 2 and 3, and compounds 5-18 described in Patent Document 4). [ka]

[0083] 1) Powder X-ray diffraction Powder X-ray diffraction measurements were performed according to the powder X-ray diffraction measurement method described in the general test methods of the Japanese Pharmacopoeia under the following measurement conditions. (Device) Rigaku MiniFlex600RINT-TTRIII (How to operate) Detector: High-speed one-dimensional detector (D / t e X Ultra2) and variable knife edge Measurement method: Reflection method Light source type: Cu tube Wavelength used: CuKα ray Tube current: 15mA Tube voltage: 40Kv Sample plate: Non-reflective plate (silicon) X-ray incidence angle (θ): 4-40°, sampling width: 0.02° (result) Compound 5: The following diffraction pattern was observed: Powder X-ray diffraction 2θ(°): 4.5, 8.9, 9.7, 9.9, 11.4, 12.0, 13.5, 14.3, 18.0, 19.2, 19.5, 20.0, 20.7, 21.7, 21.9, 22.9, 28.9, 29.2 Comparative compound: showed a broad halo pattern. 2) UV absorption The detector for the liquid chromatography was a photodiode array (PDA) detector, and the UV spectrum and peak area values ​​for the peaks corresponding to each compound in the obtained chromatogram were measured, and the relative differences in the magnitude of the molar absorbance coefficients of each compound were estimated. The measurement conditions are as follows: (Device) HPLC system: Shimadzu Nexera X2 UHPLC Detector: SPD-M30A (PDA), Measurement wavelength range: 190-400 nm (How to operate) Compound 5: Mobile phase: [A] is an aqueous solution containing 10 mM ammonium formate, [B] is acetonitrile Gradient: A linear gradient from 5% to 95% solvent [B] in 17 min, followed by a 3 min hold at 95% solvent [B]. Column: XBridge® Phenyl (3.5 μm, id 4.6 x 150 mm) (Waters) Flow rate: 1.0 mL / min Sample solution concentration: approx. 0.48 mg / mL Injection volume: 10μL Comparison compounds: Mobile phase: 5% acetonitrile in water Column: COSMOSIL (registered trademark) HILIC (5.0 μm, id 4.6 x 250 mm) (Nacalai Tesque) Flow rate: 1.0 mL / min Sample solution concentration: Approximately 10 mg / mL Injection volume: 1μL (result) Compound 5: Maximum absorption wavelength 221 nm Comparative compound: maximum absorption wavelength 195 nm (when analyzing using a general UV detector, no maximum absorption wavelength is observed in the practical wavelength range >210 nm). The molar absorption coefficient of Compound 5 at 221 nm was estimated to be about 5 times that of the comparative compound at 195 nm, and the molar absorption coefficient of Compound 5 at 221 nm was estimated to be about 40 times that of the comparative compound at 221 nm. 3) Stability The analysis of compound 5 used the following conditions. Mobile phase: [A] is 60 mM ammonia-ammonium acetate buffer solution (pH 8.0), [B] is acetonitrile Gradient: 15% solvent [B] for 0.5 min, followed by a linear gradient of 15%-50% solvent [B] over 2.5 min, a linear gradient of 50%-65% solvent [B] over 9 min, a linear gradient of 65%-95% solvent [B] over 3 min, followed by a linear gradient of 95% solvent [B] for 1 min. Column: ACQUITY UPLC® BEH Phenyl (1.7 μm, id 2.1 x 100 mm) (Waters) Flow rate: 0.3 mL / min UV detection wavelength: 295 nm The analysis of the comparative compounds was carried out under the following conditions. Mobile phase: [A] is an aqueous solution containing 10 mM ammonium formate, [B] is methanol Gradient: 97% solvent [B] maintained for 20 min. Column: Triart® C8 (3 μm, id 4.6 x 100 mm) (YMC) Flow rate: 1.0mL / min Injection volume: 10μL Detector: Corona CAD, Corona CAD detection conditions: 60Hz, BCD polarity +, pressure 35±1psi, total flow rate 1.53mL / min (result) Compound 5 (40℃): 99.6% (initial) → 99.6% (after 7 days) → 99.7% (after 50 days) Comparative compound (-20°C): 54.3% (initial) → 42.0% (after 71 days) → 33.8% (after 7 months) [Industrial Applicability]

[0084] Using the production method of the present invention, a high-quality biantennary lipid-linked oligonucleotide can be efficiently produced. The intermediate of the present invention is particularly useful in the production method.

Claims

1. A compound represented by the formula below or a salt thereof. 【Chemistry 1】

2. The formula 【Chemistry 2】 and a compound represented by the formula: Formula (III): 【Chemistry 3】 (In the formula, Support means a solid phase support, Oligonucleotide means an oligonucleotide, 3' means the 3' end of the oligonucleotide, and 5' means the 5' end of the oligonucleotide. W means a single bond or a group represented by the formula: 【Chemistry 4】 (In the formula, Z 1 is O or S, R 10 and R 11 are each independently alkyl or alkenyl; The terminal alkylene in the formula is bonded to the oxygen atom at the 3' end of the oligonucleotide, and the terminal oxygen atom in the formula is bonded to a solid support. 【Chemistry 5】 (In the formula, Z 2 is O or S, Support, Oligonucleotide, 3', 5' and W are as defined above, In the presence of a cleavage reagent and a deprotection agent, the protecting group in the compound represented by formula (IV)' is deprotected and the compound is cleaved from the solid support to obtain a compound represented by formula (V)': 【Chemistry 6】 (wherein each symbol is as defined above, and when W is any of the groups represented by formulae (a) to (d) above, the terminal oxygen atom in formulae (a) to (d) is bonded to a hydrogen atom), The compound represented by formula (V)', Formula (VI): R X1 -C(=O)-L 1 (In the formula, R X1 is alkyl or alkenyl; L 1 is OH or a leaving group, Formula (VII)': 【Chemistry 7】 A method for producing a compound represented by the formula: (wherein each symbol is as defined above).

3. The formula 【Chemistry 8】 and a compound represented by the formula: Formula (III): 【Chemistry 9】 (In the formula, Support means a solid phase support, Oligonucleotide means an oligonucleotide, 3' means the 3' end of the oligonucleotide, and 5' means the 5' end of the oligonucleotide. W means a single bond or a group represented by the formula: 【Chemistry 10】 (In the formula, Z 1 is O or S, R 10 and R 11 are each independently alkyl or alkenyl; The terminal alkylene in the formula is bonded to the oxygen atom at the 3' end of the oligonucleotide, and the terminal oxygen atom in the formula is bonded to a solid support.) 【Chemistry 11】 (In the formula, Z 2 is O or S, Support, Oligonucleotide, 3', 5' and W are as defined above, In the presence of a cleavage reagent and a deprotection agent, the protecting group in the compound represented by formula (IV)' is deprotected and the compound is cleaved from the solid support to obtain a compound represented by formula (V)': 【Chemistry 12】 (wherein each symbol is as defined above, and when W is any of the groups represented by the above formulae (a) to (d), the terminal oxygen atom in the formulae (a) to (d) is bonded to a hydrogen atom), The compound represented by formula (V)', Formula (VI): R X1 -C(=O)-L 1 (In the formula, R X1 is alkyl or alkenyl; L 1 is OH or a leaving group.) to give a compound represented by formula (VIII)': 【Chemistry 13】 (wherein each symbol has the same meaning as defined above), The compound represented by formula (VIII)', Formula (IX): R X2 -C(=O)-L 2 (In the formula, R X2 is alkyl or alkenyl; L 2 is OH or a leaving group. 【Chemistry 14】 A method for producing a compound represented by the formula: (wherein each symbol is as defined above).

4. R X1 is alkyl having 8 to 30 carbon atoms or alkenyl having 8 to 30 carbon atoms, R X2 is alkyl having 1 to 29 carbon atoms or alkenyl having 2 to 29 carbon atoms, The number of carbon atoms is R X1 The method according to claim 3, wherein the number of carbon atoms in the alkyl or alkenyl is less than or equal to 1.

5. The method according to any one of claims 2 to 4, wherein the cleavage and deprotection reagent comprises butylamine and / or benzylamine.

6. The method according to any one of claims 2 to 5, further comprising a step of washing compound (V)' with an organic solvent.

7. Obtaining compound (VII)' or (X)' by the process according to any one of claims 2 to 6; The method includes a step of annealing an oligonucleotide comprising a sequence capable of hybridizing to the oligonucleotide of compound (VII)' or (X)' to form a double strand, A method for producing double-stranded oligonucleotides.

8. The double stranded oligonucleotide has the formula: 【Chemistry 15】 The method according to claim 7, wherein the oligonucleotide is a double-stranded oligonucleotide having a strand represented by the formula: and a strand represented by one of the formulas below: formula: 【Chemistry 16】 ,formula: 【Chemistry 17】 ,formula: 【Chemistry 18】 ,formula: 【Chemistry 19】 ,formula: 【Chemistry 20】 and the formula: 【Chemistry 21】

Citation Information

Patent Citations

  • Immunostimulatory composition and method of use thereof

    JP2015514108A

  • Oligonucleotide micelles

    WO2010071852A2

  • Immunostimulatory compositions and methods of use thereof

    WO2013151771A1

  • Alkyne phosphoramidites and preparation of spherical nucleic acid constructs

    WO2015012912A2

  • Nucleic acid derivative having immunostimulatory activity

    WO2017057540A1